

Estimation of the Effect of Phospholipase Extracted from *Candida Albicans* on Human Lymphocytes Using MTT Assay (In Vitro Study)

Saif Talib Jasim

Al-Qaim Education Dept., General Directorate of Education in Anbar, Ministry of Education, Iraq

Received: 2025, 15, Sep

Accepted: 2025, 21, Oct

Published: 2025, 04, Nov

Copyright © 2025 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).



Open Access

<http://creativecommons.org/licenses/by/4.0/>

Annotation: Background & aim: One of the common fungal illnesses brought on by the genus *Candida* is candidiasis. Clinical manifestations include everything from mucocutaneous colonization to deadly infections like candidemia that spread widely. So, the current investigation was aimed to estimate of the effect of phospholipase (PL) extracted from *Candida albicans* on human lymphocytes using MTT assay (in vitro study).

Materials & methods: Between September 2024 and April 2025, 180 married patients with VVC symptoms had their vaginal swabs taken at Al-Yarmok Hospital in Baghdad, Iraq. The age range of the patients ranged from 20 to 60 years. After being combined with 10% KOH, the initial batch of vaginal swab samples was inspected under a microscope to check for the presence of *Candida*. Sabouraud Dextrose agar (SDA) was used to hold the second round of vaginal swab samples. The phospholipase production of the isolates was assayed using the egg yolk agar plate. The effect of the enzyme on lymphocytes was tested using MTT assay.

Results: Using a 10% KOH solution, 180 samples were directly inspected under a microscope; of these, 51(28.3%) were found to be positive and 129(71.7%) to be negative. The results showed that after 24 hours of incubation, lymphocyte inhibitory rate was 9.7% at 5 μ L of PL, while at 10 μ L of PL, lymphocyte inhibitory rate was 13.2%, and at 15 μ L of PL, lymphocyte inhibitory rate was 16.0%. After 48 hours of incubation, it was found that at 5 μ L of phospholipase, lymphocyte inhibitory rate was 14.60%, while at 10 μ L of PL, inhibitory rate inhibition was 24.70%, and at 15 μ L of PL, inhibitory rate inhibition was 37.40%. After 72 hours of incubation, it was found that at 5 μ l of PL, the inhibitory rate of lymphocytes was 38.1%, while at 10 μ l of PL, the inhibitory rate of lymphocytes was 59.2%, and at 15 μ l of PL, inhibitory rate of lymphocytes was 76.34%.

Conclusion: it is concluded that the phospholipase enzyme is considered one of the most important causes that increase the risk of infection with vulvovaginal candidiasis (VVC).

Keywords: candidiasis, phospholipase, inhibitory rate, MTT assay, VVC.

Introduction

In immunocompromised patients, opportunistic yeasts called *Candida* species can cause a broad range of infections, from superficial to widespread [1,2]. The most aggressive of the *Candida* species, *Candida albicans*, can infect disabled humans with several types of candidiasis. A number of variables were identified as pathogenic for *Candida albicans* pathogenesis. The literature has focused primarily on phenotypic flipping, adhesion to host tissues, germ tube development, secreted aspartyl proteinases, and phospholipases [3,4]. Both hydrolytic enzymes have the ability to destroy cell membranes. Phospholipase A, B, C, and D are the four forms of phospholipases that have been identified in *Candida albicans*. The pathophysiology of infections and invasion of mucosal epithelia is significantly influenced by *C. albicans* extracellular phospholipases [3].

Furthermore, a number of investigations have demonstrated that clinical isolates of *Candida albicans* exhibit elevated extracellular phospholipase activity [4,5]. The amount of phospholipase produced by *C. albicans* isolated from commensals and infection cases was compared by Pinto et al. [6]. They noticed that *C. albicans* with infection sources had increased levels of phospholipase activity. A study by Farina et al. [7] found that 14.5% of vaginal strains of *C. albicans* lacked phospholipase activity, whereas 40.6% of isolates exhibited significant phospholipase production. Basu et al. [8] examined the phospholipase activity of *Candida albicans* isolated from vaginal and urine samples. Phospholipase activity (Pz value) was reported to be 0.82-0.86 in 66.6% of vaginal isolates and 0.84-0.89 in 60% of urine isolates. Despite the fact that Iran has a number of studies on *Candida* and candidiasis [5,9,10], little is known about their phospholipase activity. So, the current investigation was aimed to estimate of the effect of phospholipase extracted from *Candida albicans* on human lymphocytes using MTT assay (in vitro study)

Materials & methods

Sample collection

Between September 2024 and April 2025, 180 married patients with VVC symptoms had their vaginal swabs taken at Al-Yarmok Hospital in Baghdad, Iraq. The age range of the patients ranged from 20 to 60 years. Using sterilized cotton swabs, vaginal samples were taken. Two vaginal swabs were obtained from every patient. They quickly put the swab stick back in its case. After being given a number and labeled with the patient's name, it was brought to the private scientific laboratory.

Direct examination of samples

After being combined with 10% KOH, the initial batch of vaginal swab samples was inspected under a microscope to check for the presence of *Candida*. The diagnosis of candidiasis was made possible by the presence of both hyphae and budding yeast cells [11].

Samples culturing and isolating *Candida* species

SDA containing 1% chloramphenicol (HIMEDIA, India) was used to cultivate the second set of vaginal swab samples [12]. After that, each agar plate was placed in an incubator set at 37° C, and for seven days, it was checked daily for growth [13]. To verify *Candida* growth, the colonies from the SDA plate were stained with Gram stain [14]. HiCrome™ *Candida* Differential agar (HiMedia, India) was used to inoculate all isolated colonies, and they were then cultured for 48 hours at 37°C [15].

Phospholipase production

Price et al. [16] used the egg yolk agar plate method to measure the isolates' phospholipase production. But changes were made to the process, such as using egg yolk and Sabouraud Dextrose Broth (SDB) to extract the enzyme from the fungus. The medium was removed after three to seven days, centrifuged, and the enzyme-containing filtrate was extracted. The De Haas et al. method was used to confirm the presence of the phospholipase enzyme following the extraction process [17]. The presence of the enzyme was thought to be indicated by the medium becoming acidic and the pH concentration changing.

Lymphocyte culture

After obtaining five milliliters of blood from the peripheral vein. The volunteer's blood was carefully rolled and sucked into heparinized tubes. Using the separating solution (Human lymph prep; sp. g=1.077 g/l), a general lymphocyte separation methodology [18] was carried out to gather lymphocyte pellets by centrifuging samples for 30 minutes at 2000 rpm. Following multiple washes with Roswell Park Memorial Institute (RPMI) media and centrifugation for 10 minutes at 2000 rpm, the recovered lymphocyte cells were suspended in a 10 ml complete growth medium. As part of everyday work, the haemato-cytometer chamber and trypan blue solution dye were used to count live lymphocytes.

Determining the effect of phospholipase using MTT assay

Several sterile phospholipase concentrations, including 5, 10, and 20 μl , were applied to the sample's suspended separated lymphocyte cells using a 96-well microplate. The cells were then incubated for 20 hours at 37°C in a CO₂ incubator [18]. Untreated lymphocyte cells from the sample, suspended in the medium, served as the negative control. All wells were filled with 2 mg/ml of MTT dye, which was then incubated for 4 hours to allow living cells to metabolize it. After dissolving the purple crystals with a dimethyl sulfoxide (DMSO) solution, an ELISA reader was used to measure the wavelength at 620 nm. The percentage of lymphocytes viability was calculated as follows:

$$\text{Lymphocytes viability} = (\text{Absorbance of the test/negative control}) \times 100$$

Results & Discussion

Isolation of *C. albicans*

For the current study, vaginal swabs from vulvovaginitis-affected women were collected. 180 samples were examined directly under a microscope using a 10% KOH solution; 51 (28.0%) of these were determined to be positive and 129 (71.7%) to be negative. Figure 1 and Table 1.

Table (1): Distribution of positive cultured cases

Procedures	Samples	Positive samples	
		No.	%
Direct examined by 10% KOH	180	51	28.3
Culturing Procedure	180	51	28.3



Figure (1): colonies of *C. albicans* on SDA.

The findings of this investigation are consistent with those of Saeed and Saadallah [19], who gathered samples from Duhok Province hospital patients. When these isolates were put onto CHROM agar, the most prevalent yeast was discovered to be *Candida albicans*. Mohsin and Ali [20] identified each isolate both macroscopically and microscopically after swab incubation on Sabour and dextrose agar (SDA). Microscopic analysis was employed by Hussain et al. [21] to identify the *Candida* isolates. To find yeasts, Ozcan et al. [22] employed traditional techniques including chrom agar and microscopic morphology. Of the 182 isolates, *Candida albicans* and *Candida glabrata* were detected. The chromogenic medium exhibited a 92.9% effectiveness rate against *Candida albicans* after 72 hours. Because members of the genus *Candida* are commensal, it is essential to distinguish between infection and colonization when identifying invasive candidiasis in a laboratory setting. From a serological standpoint, various kinds of the antibodies shown in each circumstance might make this separation easier [23–24].

Determining the effect of phospholipase using MTT assay

After the phospholipase enzyme was extracted from *Candida albicans* (Fig: 2), the test was performed. Using a 96-well microplate, the sample's suspended isolated lymphocyte cells were exposed to various sterile phospholipase concentrations, such as 5, 10, and 20 μL , and then incubated for 20 hours at 37°C in a CO_2 incubator.



Figure (2): Extraction of phospholipase enzyme from *Candida albicans* fungi

Figure 3 showed MTT assay results for three phospholipase concentrations that affected normal human lymphocytes after 24 h exposure. The results showed that after 24 hours of incubation, lymphocyte inhibitory rate was 9.7% at $5\mu\text{L}$ of phospholipase, while at $10\mu\text{L}$ of phospholipase, lymphocyte inhibitory rate was 13.2%, and at $15\mu\text{L}$ of phospholipase, lymphocyte inhibitory rate was 16.0% (Figure 3). After 48 hours of incubation, it was found that at $5\mu\text{L}$ of phospholipase, lymphocyte inhibitory rate was 14.60%, while at $10\mu\text{L}$ of phospholipase, inhibitory rate inhibition was 24.70%, and at $15\mu\text{L}$ of phospholipase, inhibitory rate inhibition was 37.40% (Figure 4). After 72 hours of incubation, it was found that at 5 μL of phospholipase, the inhibitory rate of lymphocytes was 38.1%, while at 10 μL of phospholipase, the inhibitory rate of lymphocytes was 59.2%, and at 15 μL of phospholipase, inhibitory rate of lymphocytes was 76.34% (Figure 5).




Figure (3): lymphocyte inhibitory rate after 24hr.




Figure (4): lymphocyte inhibitory rate after 48hr.




Figure (5): lymphocyte inhibitory rate after 72hr.

Infections with candidiasis have been much more common over the past 20 years [25, 26]. Due to this rise, there is now a great deal of interest in studying the pathophysiology of *Candida* as well as methods for preventing and controlling this clinically significant fungus. Additionally, there has been interest in using candidate virulence factors as a potential tool for creating innovative treatments to combat candidiasis [27, 28]. These virulence factors include phenotypic switching, extracellular proteinases and phospholipases, adhesion, and germination [29,30,31]. The phospholipase enzyme was discovered to be very effective in preventing the proliferation of isolated human lymphocytes, which raises the risk of *Candida albicans* infection. According to a study, *C. albicans* blood isolates often release significantly more PL than isolates from healthy people's oral cavities [32], wounds, or urine [33]. Depending on the host milieu, the three phospholipase activities (PLB, LPL, and LPTA) may have varying proportional roles in fungal pathogenesis. It has been demonstrated that phospholipase's LPL and LPTA activities can reacylate lysophospholipids and undo the harm that other released cryptococcal components have done to neutrophils [34]. To enter host cells, microbes must break through and destroy the outer cell envelope. This transmigration process is most likely mediated by physical, enzymatic, or a combination of the two. Phospholipids and proteins are the primary chemical constituents of the host cell membrane. Therefore, enzymes like phospholipases and proteinases that can hydrolyze these chemical kinds are most likely responsible for the membrane disruption processes that occur during host cell invasion. By cleaving phospholipids, phospholipases result in membrane instability and cell lysis [35]. Phospholipases have been implicated in the lysis, damage, and

penetration of host cells by *Candida albicans* [36]. Phospholipases are therefore among the virulence agents that damage host cells [35,37]. This explains the high inhibition rate of lymphocytes by phospholipase isolated from *Candida albicans* in the present study.

Conclusions

Based on the study results, it is concluded that the phospholipase enzyme is considered one of the most important causes that increase the risk of infection with vulvovaginal candidiasis (VVC), as it has the ability to inhibit and kill lymphocytes, which are a major part of the immune cells against infection with various microorganisms.

References

1. Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and mechanisms of antifungal resistance. *Antibiotics (Basel)* 2020; 9 :305-312
2. Amini N, Mohammadi R. Phospholipase activity of *Candida* species isolated from diabetic patients. *Adv Biomed Res.* 2023; 12:11-19
3. da Costa KRC, Ferreira JC, Komesu MC, Candido RC. *Candida albicans* and *Candida tropicalis* in oral candidosis: quantitative analysis, exoenzyme activity, and antifungal drug sensitivity. *Mycopathologia.* 2009; 167: 73-9.
4. Samaranayake YH, Dassanayake RS, Jayatilake JAMS, et al. Phospholipase B enzyme expression is not associated with other virulence attributes in *Candida albicans* isolates from patients with human immunodeficiency virus infection. *J Med Microbiol.* 2005; 54: 583-93.
5. Zarei Mahmoudabadi A, Keradmand AR, Enayatollahi N. Frequency of candiduria in inpatients and outpatients in department of urology, Golestan hospital, Ahvaz, Iran. *IJKD.* 2009; 3: 114-5.
6. Pinto E, Ribeiro IC, Ferreira NJ, Fortes CE, Fonseca PA, Figueiral MH. Correlation between enzyme production, germ tube formation and susceptibility to fluconazole in *Candida* species isolated from patients with denture-related stomatitis and control individuals. *J Oral Pathol Med.* 2008; 37: 587-92
7. Farina C, Saleri N, Lombart JP, et al. Epidemiological phenotypic characteristics of vaginal yeasts at the Comoros. *Mycoses.* 2009; 52: 458-61.
8. Basu S, Gugnani HC, Joshi S, Gupta N. Distribution of *Candida* species in different clinical sources in Delhi, India, and proteinase and phospholipase activity of *Candida albicans* isolates. *Rev Iberoam Micol.* 2003; 20: 137-40.
9. Jamilian M, Mashadi E, Sarmadi F, et al. Frequency of vulvovaginal candidiasis species in nonpregnant 15-50 years old women in spring 2005 in Arak. *J Arak Uni Med Sci.* 2007; 2: 7-14.
10. Jafari Nodoushan AA, Dehghani M, Mirbagheri SM. In vitro antifungal effect of aqueous Garlic (*Allium sativum*) extract and its combination with fluconazole against five common clinical *Candida* isolated from candidiasis lesions. *J Kerman Uni Med Sci.* 2007; 3: 153-62.
11. Shawaky SM, Shammari MMA, Sewelliam MS, Ghazal AAER, Amer AN, Shawaky SM, et al. (2022). A study on vaginitis among pregnant and non-pregnant females in Alexandria, Egypt: An unexpectedly high rate of mixed vaginal infection. *AIMSMICRO.* May 5;8(2):167–77.
12. Matare T, Nziramasanga P, Gwanzura L, Robertson V. (2017). Experimental Germ Tube Induction in *Candida albicans*: An Evaluation of the Effect of Sodium Bicarbonate on Morphogenesis and Comparison with Pooled Human Serum. *Biomed Res Int.* 2017 Jun 5:1976273.

13. Al Halteet S, Abdel-Hadi A, Hassan M, Awad M. (2020). Prevalence and Antifungal Susceptibility Profile of Clinically Relevant *Candida* Species in Postmenopausal Women with Diabetes. Fernandes L, editor. *BioMed Research International*. 2020 Nov 26:1–9.
14. Krishnasamy L, Krishnakumar S, Santharam P, Saikumar C. (2018). Isolation and identification of *Candida* Species in Patients with Vulvovaginal Candidiasis. *J Pure Appl Microbiol*. Dec 30;12(4):2269–73.
15. Kaup S, Sankarankutty J, Balasubrahmanya HV, Kulkarni S, Nirmala M. (2016). Speciation of *Candida* using HiCrome *Candida* Differential Agar. *IntJCurrMicrobiolAppSci*. Jul 15;5(7):267–74.
16. Price M. F., Wilkinson I. D., Gentry L.-O. (1982). Plate method for detection of phospholipase activity in *Candida albicans*. *Sabouraudia*, 20, 7-14.12.
17. De Haas GH, Postema NM, Nieuwenhuizen W and van Deenen LLM. (1968). Purification and properties of phospholipase A from porcine pancreas. *Biochim. Biophys. Acta* 159,103-117.
18. Freshney RI. *Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications*, sixth edition. Wiley Online Library, 2010
19. Saeed A. S., Saadullah A. A. M. Isolation, Identification and Antifungal Susceptibility Testing of *Candida* Species from Dermatologic Specimens in Duhok Province. *Zanco Journal of Pure and Applied Sciences*, 2019; 31(4): 1-8.
20. Mohsin Z. A., Ali W. S. Antagonistic Activity of Bacteriocin-producing *Lactobacillus* Against *Candida* spp. *Iraqi Journal of Science*, 2021; 7: 2153-2162.
21. Hussain N. S., Latif I. I., Obaid H. H. Antimicrobial Activity of Non-bond Colicin on *Candida albicans* Biofilm. *Iraqi Journal of Science*, 2020; 4: 2831-2837.
22. Ozcan K., Ilkit M., Ates A., Turac-Bicer A. Demirhindi H. Performance of Chromogenic *Candida* agar and CHROMagar *Candida* in recovery and presumptive identification of monofungal and polyfungal vaginal isolates," *Med Mycol.*, 2010; 48(1): 29-34.
23. Ponton J, Moragues MD, Quindos G. Non-culture based diagnostics. In: Calderone and R.A. , editor. *Candida and candidiasis*. Washington, D.C., American Society for Microbiology; 2002. pp. 395–425.
24. Quindos G, Moragues MD, Ponton J. Is there a role for antibody testing in the diagnosis of invasive candidiasis? *Rev Iberoam Micol*. 2004;21:10–14.
25. Pittet D., Tarrara D., Wenzel R. P. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality, 1985, p. 17–24.
26. Pfaller M., and Wenzel R. Impact of the changing epidemiology of fungal infections in the 90's. *Eur. J. Clin. Microbiol. Infect. Dis*. 1992; 11:287–291.
27. Perfect J. R. Fungal virulence genes as targets for antifungal chemotherapy. *Antimicrob. Agents Chemother*. 1996; 40:1577–1583.
28. Georgopapadakou, N. H., Walsh T. J. Antifungal Agents: chemotherapeutic targets and immunologic strategies. *Antimicrob. Agents Chemother*. 1996; 40:279–291.
29. Klotz, S. Fungal adherence to the vascular compartment: a critical step in the pathogenesis of disseminated candidiasis. *Clin. Infect. Dis*. 1992; 14:340–347.
30. Ibrahim A. S., Mirbod F., Filler S. G., Banno Y., Cole T., Kitajima Y., Edwards J., Nozawa Y., Ghannoum M. A. Evidence implicating phospholipase as a virulence factor of *Candida albicans*. *Infect. Immun*. 1995; 63:1993–1998.

31. Soll D. R. Gene regulation during high frequency switching in *Candida albicans*. *Microbiology*. 1997; 143:279–288.
32. Ibrahim, A. S., Mirbod, F., Filler, S. G., Banno, Y., Cole, G. T., Kitajima, Y., Edwards, J. E. Jr., Nozawa, Y., and Ghannoum, M. A. Evidence implicating phospholipase as a virulence factor of *Candida albicans*. *Infect. Immun.* 1995; 63: 1993–1998
33. Price, M. F., Wilkinson, I. D., and Gentry, L. O. Plate method for detection of phospholipase activity in *Candida albicans*. *Sabouraudia*. 1982; 20, 7–14.
34. Santangelo, R. T., Chen, S. C., Sorrell, T. C., and Wright, L. C. Detection of antibodies to phospholipase B in patients infected with *Cryptococcus neoformans* by enzyme-linked immunosorbent assay (ELISA). *Med. Mycol.* 2005; 43: 335–341.
35. Salyers A, Witt D. Virulence factors that damage the host. In: Salyers A, Witt D, editors. *Bacterial pathogenesis: a molecular approach*. Washington, D.C.: ASM Press; 1994. pp. 47–62.
36. Leidich S D, Ibrahim A S, Fu Y, Koul A, Jessup C, Vitullo J, Fonzi W, Mirbod F, Nakashima S, Nozawa Y, Ghannoum M A. Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of *Candida albicans*. *J Biol Chem*. 1998; 273: 26078–26086.
37. Mirbod F, Banno Y, Ghannoum M A, Ibrahim A S, Nakashima S, Kitajima Y, Cole G T, Nozawa Y. Purification and characterization of lysophospholipase-transacylase (h-LPTA) from a highly virulent strain of *Candida albicans*. *Biochim Biophys Acta*. 1995;1257:181–188.